From: Aberrant methylation of yes-associated protein (YAP1) as a potential biomarker in breast cancer
Variable | Total n (%) | Unmethylated Nā=ā16 (%) | Methylated Nā=ā34 (%) | Test of Significance | p value |
---|---|---|---|---|---|
Age (years) | |||||
āā¤ā50 | 31 (62) | 12 (38.7) | 19 (61.3) | Ļ2ā=ā1.688 | 0.194 |
āĖĀ 50 | 19 (38) | 4 (21.1) | 15 (78.9) | ||
BMI (kg/m2) | |||||
āā¤ā25 | 14 (28) | 6 (42.9) | 8 (57.1) | Ļ2ā=ā1.053 | FEpā=ā0.330 |
āĖĀ 25 | 36 (72) | 10 (27.8) | 26 (72.2) | ||
Menopausal state | |||||
āPremenopausal | 17 (34) | 4 (23.5) | 13 (76.5) | Ļ2ā=ā0.849 | 0.357 |
āPostmenopausal | 33 (66) | 12 (36.4) | 21 (63.6) | ||
Histopathological type | |||||
āDuctal | 34 (68) | 12 (35.3) | 22 (64.7) | Ļ2ā=ā0.534 | MCpā=ā0.884 |
āLobular | 12 (24) | 3 (25) | 9 (75) | ||
āOthers | 4 (8) | 1 (25) | 3 (75) | ||
Tumor stage | |||||
āI | Ā | Ā | Ā | Ļ2ā=ā34.124* | <ā0.001* |
āII | 18 (36) | 15 (83.3) | 3 (16.7) | ||
āIII | 22 (44) | 1 (4.5) | 21 (95.5) | ||
āIV | 10 (20) | 0 (0) | 10 (100) | ||
Tumor size | |||||
āā¤ā2ācm | 3 (6) | 2 (66.7) | 1 (33.3) | Ļ2ā=ā1.763 | FEpā=ā0.237 |
ā>ā2ācm | 47 (94) | 14 (29.8) | 33 (70.2) | ||
Axillary lymph node involvement | |||||
āYes | 47 (94) | 14 (29.8) | 33 (70.2) | Ļ2ā=ā1.763 | FEpā=ā0.237 |
āNo | 3 (6) | 2 (66.7) | 1 (33.3) | ||
āNo | 40 (80) | 16 (40) | 24 (60) | ||
Estrogen receptor status (ER) | |||||
āPositive | 42 (84) | 13 (31) | 29 (69) | Ļ2ā=ā0.132 | FEpā=ā0.699 |
āNegative | 8 (16) | 3 (37.5) | 5 (62.5) | ||
Progesterone receptor status (PR) | |||||
āPositive | 43 (86) | 14 (32.6) | 29 (67.4) | Ļ2ā=ā0.044 | FEpā=ā1.000 |
āNegative | 7 (14) | 2 (28.6) | 5 (71.4) | ||
HER2 expression status | |||||
āOverexpression | 16 (32) | 2 (12.5) | 14 (87.5) | Ļ2ā=ā4.112* | 0.043* |
āNon-overexpression | 34 (68) | 14 (41.2) | 20 (58.5) | ||
CA15ā3 (U/ml) | |||||
āMeanāĀ±āSD | 37.49āĀ±ā28.17 | 28.78āĀ±ā12.94 | 41.59āĀ±ā32.37 | tā=ā1.520 | 0.135 |
āMedian (mināmax) | 34 (11ā190) | Ā | Ā |